Obesity drug dosing mystery: can lean mass predict acyclovir needs?
NCT ID NCT05589688
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to improve how acyclovir is dosed in people with obesity. Researchers will measure lean body mass and kidney function in 20 healthy volunteers with different BMIs to see if these factors predict how the body clears the drug. The goal is to create better dosing guidelines for obese patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Toulouse Hospital
RECRUITINGToulouse, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?